Elevated levels of combustion-derived particulate matter (CDPM) are a risk factor for the development of lung diseases such as asthma. Studies have shown that CDPM exacerbates asthma, inducing acute lung dysfunction and inflammation; however, the impact of CDPM exposure on early immunological responses to allergens remains unclear.
INTRODUCTION
Exposure to elevated levels of ambient particulate matter (PM) during early life has long been associated with the development of acute/chronic pulmonary morbidities (e.g., asthma) later in life. 1 Although epidemiology suggests young children are most affected, 2,3 relatively little data, mechanistic or otherwise, exist detailing the impacts of PM exposure on this immunologically immature population. 4 Exacerbation of pulmonary dysfunction has been demonstrated in allergen-sensitized adult mice exposed to PM during allergen challenge. 5, 6 Although clinically relevant, these studies focus heavily on the acute effects of PM exposure during the ''challenge'' phase of asthma that bypasses possible PM effects during earlier sensitization. In addition, adult mice with mature immune systems respond very differently than infants; therefore, failing to inform us about the role of early-life exposure in the development of the airway disease itself.
Our previous work with combustion-derived particulate matter (CDPM) has shown that acute early-life exposure induces oxidative stress and inflammation in the lung. 7 These effects are accompanied by significant pulmonary remodeling including airway smooth muscle thickening brought upon by CDPM exposure-induced epithelial-to-mesenchymal transitions. 8 Bronchiolar epithelial disruption caused by CDPM exposure imparts a potentially important change in ''programming'' of subsequent adaptive immune responses primarily through actions of dendritic cells (DCs), the professional antigen-presenting cell. When E-cadherin-mediated cell-cell junctions are disrupted, DCs undergo a phenotypic shift toward the promotion of tolerance. 9 In the present study, we sought to determine the role of early life exposure to PM on the development of allergic asthma (i.e., PM exposure before and during allergen sensitization and challenge). The question arose because of the lack of data on the impacts of PM exposure in infants and the lack of studies examining the effects of allergen exposure during PM exposure in infants, an equally clinically relevant scenario. We found that exposure to CDPM during early life creates an immunosuppressive environment in the lung that impairs T effector cell production in vivo. Combining CDPM exposure with exposure to house dust mite allergen (HDM) in a mouse model of allergic asthma, 10 we showed that infant mice exposed to CDPM and HDM fail to develop certain hallmarks of asthma while maintaining others. Interestingly, this immunosuppression is lost over time; mice that exhibited dampened T-helper type 2 (Th2) effector responses early in life developed an exacerbated asthma phenotype when rechallenged with allergen as adults. Taken together, our data suggest a mechanism whereby CDPM exposure during infancy alters pulmonary immune responses and modulates long-term pulmonary inflammatory disease development.
RESULTS

Exposure to CDPM modulates early-life allergic airway disease in mice
To investigate the impact of CDPM exposure in an early-life model of allergic airways disease, we exposed mouse pups beginning at 3 days of age to CDPM (DCB) before and during the establishment of an HDM model of asthma (Figure 1a ). Twenty-four hours following the final exposure day, pulmonary function was analyzed by flexiVent ( Figure 1b) . Interestingly, airway hyper-responsiveness (AHR), a physiological hallmark of asthma, was only observed in the Air/HDM mice and not DCB/HDM mice. Following functional tests, bronchoalveolar lavage (BAL) fluid was collected and analyzed for cellularity ( Figure 1c) . A significant increase in total cell number occurred only in Air/HDM mice. Furthermore, a large increase in eosinophils, commonly seen in asthmatics, was observed only in the Air/HDM mice but was noticeably lower in the DCB/HDM mice. Lymphocyte numbers were also increased in the Air/HDM group, whereas neutrophils were equally increased in both Air/HDM and DCB/HDM mice. Cell-free BAL fluid was analyzed for cytokine content using multiplex ( Figure 1d ). As expected, Th2 cytokines (interleukin (IL)-4, IL-5) were significantly elevated in Air/HDM and DCB/HDM mice compared with respective controls; however, IL-4 was approximately threefold lower in DCB/HDM mice compared with Air/HDM mice. Other proinflammatory cytokines (IL-6, tumor necrosis factor-a) were elevated in only Air/HDM mice. Serum from these animals was analyzed for immunoglobulin (Ig) production ( Figure 1e) . Surprisingly, total IgE was statistically increased in both Air/HDM and DCB/HDM mice compared with controls and the levels were approximately threefold higher in DCB/HDM mice compared with Air/HDM mice. Conversely, HDM-specific IgE levels were significantly lower in DCB/HDM mice compared with Air/HDM mice. Total IgG 1 was elevated only in Air/HDM mice and once again HDM-specific IgG 1 levels were reduced in DCB/HDM mice compared with Air/HDM mice.
CDPM exposure decreases Th2 and Treg inflammation in early-life asthma model
IL-4-producing Th2 lymphocytes are regularly associated with allergic asthma, and the relative level of Th2 inflammation is positively correlated with asthma symptoms. 11 To study the effects of CDPM exposure on Th2 inflammation in an asthma model, the levels of Th2 lymphocytes (CD4 þ IL-4 þ ) were assessed in mice ( Figure 2) . Total CD4 þ lymphocytes were elevated in all mice given HDM relative to controls, but a statistical decrease was observed in DCB/HDM mice compared with Air/HDM (Figure 2a ). Expectedly, levels of Th2 lymphocytes were elevated in all HDM groups (Figure 2b , c). However, Th2 levels were significantly lower in DCB/HDM mice compared with Air/HDM mice. Owing to the previously observed inflammatory suppression in CDPM-exposed mice, we assessed regulatory T cell (Treg) (CD25 þ Foxp3 þ ) levels. We observed an increase in Treg cell numbers in the lungs of Air/HDM mice compared with Air mice (Figure 2d , e). Conversely, Treg levels were significantly decreased in mice exposed to DCB/HDM. Neither Th2 nor Treg cell numbers were different between Air and DCB groups.
CDPM exposure modulates mucus-associated gene expression but not airway mucus production in early-life asthma model Increased airway mucus production via goblet cell hyperplasia is commonly seen in allergic airway diseases (i.e., asthma). To determine the impact of CDPM exposure on HDM-induced mucus in the airways, we quantified mucus content in the airways using periodic acid-Schiff (PAS) staining on lung sections and mucus gene expression in the lungs (Figure 3 ). Percent mucus-positive cells (Figure 3a , inset) were found to be significantly elevated in all mice receiving HDM, with no statistical difference in DCB/HDM and Air/HDM mice ( Figure 3b ). Mucus-associated gene expression was investi gated by quantitative, real-time, reverse transcriptionpolymerase chain reaction (RT-PCR) on whole lung tissue (Figure 3c-e). Expression of Muc5b and IL13 was elevated in both groups receiving HDM relative to controls. Interestingly, Muc5ac expression was only elevated in Air/HDM mice relative to controls.
Acute CDPM exposure causes an immunosuppressive environment in the lung
Immunosuppressive effects of CDPM were investigated by measuring levels/sources of IL-10 in the lung (Figure 4a -h). After acute (five consecutive days) exposure to DCB, expression of IL10 in the whole lung tissue was elevated compared with air controls (Figure 4a ). Lung DCs (CD11c þ F4/80 À ), which are crucial determinants in adaptive immune responses, were less activated following exposure as evidenced by decreased costimulatory molecule (CD80) expression ( Figure 4b ).
Using IL-10-GFP reporter mice to discern major sources of IL-10, an increased number of IL-10-producing DCs were observed in the lungs of DCB-exposed mice (Figure 4c, d ). In addition to increased number, these DCs produced higher levels of IL-10 compared with IL-10 þ DCs from control mice as evidenced by increased MFI (Figure 4e ). Further investigation of DC subsets (mDC, MHCII hi CD11b þ ; interstitial DC, MHCII hi CD11b À ) showed interstitial DCs as the main source of DC-derived IL-10 (Supplementary Figure S1 online). Increased numbers of IL-10 þ CD4 lymphocytes were also observed in DCB-exposed mice (Figure 4f , g). These IL-10 þ cells also expressed higher levels of IL-10 compared with controls ( Figure 4h) . No difference in IL-10 production was observed in other cell types investigated (data not shown). The ability of CDPM exposure to elicit Treg responses in the lung was investigated by flow cytometry (Figure 4i , j). Following an acute exposure to DCB, pulmonary Treg (CD3 þ CD4 þ CD25 þ Foxp3 þ ) numbers were increased compared with control mice. The function of phenotypically immunosuppressive DCs resulting from CDPM exposure was investigated using an in vitro T-cell activation assay. When cocultured with antigenspecific naive CD4 þ cells from age-matched OT-II mice, lung DCs isolated from DCB-exposed mice promote significantly increased Treg and significantly decreased Th2 effector polarization compared with lung DCs isolated from control mice ( Figure 5a ). Supernatant Th2 cytokine (IL-4, IL-13) concentrations were also significantly decreased in cocultures with DCB-exposed DCs compared with control DCs ( Figure 5b) . To see if DCB-exposed DCs were capable of driving Treg-biased differentiation in vivo, we isolated pulmonary DCs from Air or DCB-exposed mice, loaded them with ovalbumin 323-339 (OVA 323-339 ) peptide in vitro, and then adoptively transferred those DCs into age-matched OT-II mice ( Figure 5c ). Similar to effector responses observed in vitro, the DCs from DCB-exposed mice generated a significantly higher Treg response in the lungs of recipient mice ( Figure 5d ). Negligible Th2 responses were observed in all groups (data not shown).
Acute CDPM exposure dampens lung T effector response in antigen-challenged OT-II mice
To model CDPM-induced immunosuppression in response to antigen, OT-II mice were exposed to DCB for 1 week starting at 3 days of age and administered OVA 323-339 (2 mg) intranasally on exposure days 5 and 7. Four days later, T effector responses were measured in the lung by flow cytometry ( Figure 6 ). Suppression of T effector cell numbers was noted in DCBexposed mice compared with controls. Specifically, decreased levels of total CD4 þ cells were observed ( Figure 6a ) and the allergen failed to elicit an increase in Th2 cell numbers ( Figure 6b ) in DCB-exposed mice. Surprisingly, Treg levels were also decreased in the lungs from allergen-challenged, DCB-exposed mice compared with controls ( Figure 6c ). No significant differences were observed in other T effector populations analyzed (Th1 and Th17; data not shown).
Mice exposed to CDPM and sensitized to OVA as neonates, then rechallenged with OVA as adults display an exacerbated asthma phenotype
To examine the effect of early-life CDPM exposure during antigen sensitization on responses to antigen later in life (i.e., as an adult), OT-II neonates (groups as in Figure 6 ) were allowed to mature until 8 weeks of age and then rechallenged with OVA 323-339 . In contrast to previously observed immunosuppression in the lungs of CDPM-exposed mice, allergic responses in mice exposed to CDPM during initial OVA sensitization as neonates were significantly elevated above all other groups (Figure 7a) . Specifically, increased levels of Th2 and Th17 cells were observed in addition to increased levels of Tregs. This group also displayed AHR ( Figure 7b ) and severe peribronchial inflammation with an apparent increase in peribronchial smooth muscle mass ( Figure 7c ). Levels of mucus were comparable in exposed and unexposed groups that were rechallenged with OVA ( Figure 7d ).
DISCUSSION
Positive correlations are observed between elevated PM levels and adverse pulmonary effects including developmental/ functional deficits that present during childhood and last into adulthood. [12] [13] [14] [15] The increasing rate of childhood asthma over recent decades, particularly in urban areas, 16 indicates a larger influential role of environmental factors like PM. Indeed, elevated PM is a factor in childhood asthma onset, 17 with the highest risk associated with traffic-related CDPM exposure during an early age. 18 The fact that early insults on the lung associate with such dire, persistent consequences is not surprising, given the immaturity of the immune system during the first three years of life. During infancy, humans display a natural tendency toward tolerance, which is believed to be extended from antimaternal immunity in utero. 19 This is also observed (and has been studied) in neonatal mice. [20] [21] [22] Despite infants and young children representing a population highly affected by both PM and asthma, there is very little data concerning the relationship of the two in the early stages of asthma development. 4 In this study, we demonstrated a temporary immunosuppressive environment in the lung in response to early-life CDPM exposure. The major determinants of adaptive immune responses, DCs, were less activated and produced more IL-10 after CDPM exposure. Within this same acute exposure time period, we observed increases in CD4 þ T cells producing IL-10, Tregs, and IL10 mRNA in the whole lung. In an isolated in vitro system, DCs from the lungs of CDPM-exposed mice promoted less Th2 differentiation and effector function including lower expression of IL-4 and IL-13 in favor of a higher Treg differentiation of naive T cells. When DCs from CDPMexposed mice were adoptively transferred into naive OT-II mice, an increase in Tregs was observed in the lungs of recipient mice. A measureable Th2 response was not observed in any group. This was not unexpected, given the weak antigen challenge with respect to the OT-II mice being challenged with OVA. When directly allergen challenged during early life, CDPM-exposed mice were unable to elicit Th2 responses, while non-exposed mice had significantly increased Th2 cell numbers. The increased numbers of Tregs in the lungs of OT-II mice exposed to CDPM ( Figure 4 ) followed by subsequent decrease of Tregs after allergen challenge ( Figure 6 ) suggests a transient Treg response to CDPM that is suppressive to all effector T proliferation to allergen, including Tregs themselves. This immunosuppression could have beneficial effects with respect to early asthma symptoms, but could lead to exacerbated allergic responses upon allergen rechallenge when suppression wanes. Indeed, our data demonstrated an exacerbation of allergic responses in mice exposed to CDPM and sensitized to OVA as infants and then rechallenged with OVA as adults. This was evidenced by AHR and increased Th2 cell numbers in lungs of adult mice exposed to CDPM during OVA sensitization as neonates (Figure 7) . Interestingly, we also observed significant Th17 cell numbers in this same group of mice even in the absence of measurable Th17 responses to OVA as neonates. A Th17-mediated response has been previously demonstrated in OVA-challenged adult OT-II mice, 23 and our previous CDPM exposure study in adult mice also shows a dominant Th17 component. 5 Therefore, it is of little surprise that combining CDPM exposure with adult OVA challenge yielded such large Th17 responses. Despite having significant pulmonary inflammation, minimal amounts of mucus were observed in these mice; we believe this to be a consequence of the use of OVA peptide as allergen and/or the use of OT-II mice. We believe that the exacerbated Th2 and Th17 responses and pathological changes induced by early-life exposure to CDPM may be responsible for the increases in asthma severity.
In an early-life HDM model of asthma, exposure to CDPM abolished AHR. This functional effect was accompanied by significant decreases in BAL total inflammation and eosinophils and Th2 cytokines (i.e., IL-6, tumor necrosis factor-a/ IL-4, respectively). A trending, but nonsignificant decrease in IL-5 was observed in BAL fluid of CDPM-exposed mice. In addition, the chemokine CXCL10, which is linked to AHR in human asthma, 24 was elevated in BAL fluid of Air/HDM mice but not CDPM-exposed HDM mice (Supplementary Figure  S1 ) and may partially explain the absence of AHR in the latter group. Furthermore, we observed decreased Th2 cell numbers in the lungs of CDPM-exposed HDM mice, which agrees with our other antigen challenge data ( Figure 6 ). Morphometric analysis of airway mucus revealed no quantifiable difference in the amount of mucus-producing cells and reverse transcription-PCR revealed no quantifiable difference in the expression of mucus-associated genes Muc5b and IL13 in the lungs of CDPM-exposed and non-exposed HDM mice. However, Muc5ac expression was decreased in the lungs of CDPM-exposed mice given HDM vs. non-exposed HDM mice.
Serum antibody responses were of note, particularly because of the contrast that the data have to the rest of the suppressive effects of CDPM on HDM asthma. Whereas CDPM-exposed HDM mice appeared to be protected from functional/ inflammatory effects of HDM, this group had approximately double the concentration of total IgE in serum. Interestingly, however, the serum concentrations of both HDM-specific IgE and IgG 1 were approximately twofold lower in CDPM-exposed HDM mice vs. non-exposed HDM mice. These data agree with CDPM-mediated immunosuppression to HDM, and also indicate a more complex adaptive immune response. The antigen specificity of the IgE that account for the increase in CDPM-exposed HDM mice is unclear, but it is possible that oxidative damage to airway cells that we have previously observed 7, 8, 25, 26 is releasing oxidized self-antigen able to initiate adaptive responses. In any case, elevated total IgE is strongly associated with development of hypersensitivity, 1 and, although our data suggest CDPM-mediated protection from the development of specific allergy (i.e., HDM asthma) during CDPM exposure, we clearly observed heightened asthma-like responses if mice were rechallenged with allergen as adults. It is possible that the elevated total IgE observed early has a role in the heightened susceptibility to allergens later in life.
Our previous work focusing on the early-life effects of CDPM exposure has shown the significant disruption airway epithelium resulting in epithelial-to-mesenchymal transitions and increased smooth muscle mass. 8 There are some in vitro and intestinal in vivo data suggesting that loss of E-cadherin interactions between DCs results in a tolerogenic DC phenotype via b-catenin transcriptional signaling. 9, 27 In this study, we show that the DC subset responsible for IL-10 production following CDPM exposure is interstitial DCs (intraepithelial resident cDCs), which rely on E-cadherin interactions to reside between airway epithelial cells. Therefore, it is possible that loss of E-cadherin interactions between epithelial cells and interstitial DCs as a result of CDPM exposure is involved in inducing tolerance here also. In agreement with this theory, we have observed b-cateninresponsive transcription events such as increases in Snai1 in CDPM-exposed mice. 8 The impact of CDPM exposure on regulation of b-catenin itself is currently being investigated by our laboratory. The suppressive effects of IL-10-producing, tolerogenic DCs have been demonstrated to increase the presence/activity of Tregs and abrogate AHR, airway eosinophilia, Th2 cytokines, and circulating HDM-specific IgE/ IgG 1 in an HDM asthma model. 28 The actions of local Foxp3 þ Tregs are vital in maintaining tolerance, 29 and the significant increase that we observed in these cells in CDPM-exposed mice in vivo coupled with the lack of Th2 differentiation/elevated Treg numbers perpetuated from the CDPM-exposed mice DCs in vitro suggests that tolerance to HDM in this respective group may also be derived from CDPM-induced tolerogenic DCs/ Tregs. Although beyond the scope of this manuscript, it is possible that following epithelial repair, E-cadherin interactions between DCs and epithelial cells release the DC from its tolerogenic state allowing ''normal'' responses to allergens/ pathogens. As adaptive T effector responses were developed to allergen during the initial CDPM exposure and allergen challenge (evidenced by HDM-specific IgE), this suggests that upon re-exposure, persisting T and B cells are able to mount a memory response to allergen. This response is unhampered by tolerogenic DCs and Tregs, allowing for an exacerbated asthma phenotype as our data show.
The inflammation-attenuating effect of PM on allergic asthma models has been previously demonstrated. When OVA-sensitized mice are coexposed to nanoparticles or mild cigarette smoke (which contains high amounts of CDPM) along with OVA, significant decreases in pulmonary inflammation (e.g., total cells, eosinophilia, BAL IL-4/IL-5) are observed along with abolishment of AHR. 30, 31 In addition, Muc5ac expression is also decreased, which agree with our data. To our knowledge, no data concerning PM and Muc5b expression exist, making it difficult to explain why we observed a difference in expression of Muc5b vs. Muc5ac or why mucus cell frequency remained unchanged by CDPM. There is evidence that Muc5b is prominent in developing lungs, while Muc5ac is not. 32 Furthermore, Muc5ac is stabilized by tumor necrosis factor-a, which was decreased in CDPM mice, while Mub5b is unaffected. 33 Differential regulation of these mucus genes is further evidence of age-dependent responses and enforces the necessity of age-appropriate studies.
In contrast to our data, IgE levels are not affected by coexposure in aforementioned studies. 30, 31 It is likely that the differences in OVA vs. HDM coexposure asthma protocols are responsible; OVA coexposure protocols require prior sensitization to OVA (i.e., intraperitoneal injections of OVA complexed to adjuvant) followed by challenge with OVA during the PM exposure, whereas in our HDM model, mice were exposed first to CDPM and exposure to CDPM continued throughout the HDM exposure. Finally, HDM is a more physiologically relevant allergen and elicits asthma in the absence of a Th2-driving adjuvant in mice. The implications of PM exposure-induced immunosuppression in the lung reach beyond allergic sensitization, and we are currently exploring this effect in the context of other disease. For example, an early immunosuppressive environment could be detrimental during contact with actual pathogen (e.g., influenza virus, Klebsiella pneumoniae, etc.) because of the inability to mount an appropriate immune response (manuscript in preparation). In conclusion, we were able to demonstrate the immunosuppressive effects of CDPM exposure, due in part to promotion of tolerogenic DCs and Treg differentiation. In the presence of this suppressive environment, antigen-specific responses were attenuated in the lung, leading to lessened overall inflammation and AHR. Despite the reduced antigen-specific effects observed, total IgE was more highly elevated in CDPM-exposed HDM mice, indicating a susceptibility to other hypersensitivity diseases. These findings illustrate a mechanism for the development of asthma and other allergic disease in the context of high PM exposure during early life. Knowledge gained from these types of age-appropriate studies is crucial to our understanding of origins of complex diseases such as asthma, and highlights the importance of preventing exposure to CDPM during early life.
METHODS
Combustion-generated particulate matter and exposures. Combustion-generated particulate matter, DCB, was generated and characterized as described previously. 7 Immediately before use, vacuum-sealed vials were opened and 5 mg DCB were suspended in 25 ml sterile saline containing 0.02% Tween-80 using sonication to monodisperse particles, giving a mean aerodynamic diameter of 0.2 mm (Supplementary Methods online). For in vivo inhalation exposures, pups were placed in a small chamber with nebulized particles for 30 min per day (beginning at 3 days of age and continuing for experiment-specific amount of time), at an average airborne PM concentration of 200 mg m À 3 , which is equivalent to that of an aboveaverage polluted urban area. Exposure conditions are based on modeling calculations (MPPD v.2.0; Supplementary Methods) to produce equivalent particle deposition per alveolus to that of a human infant exposed over 24 h.
Animals. C57BL/6J, OT-II (C57BL/6-Tg(TcraTcrb)425Cbn/J), and IL-10-GFP (B6.129S6-Il10 tm1Flv /J) reporter mice were purchased from Jackson Labs (Bar Harbor, ME), kept in ventilated cages in a specific pathogen-free environment, and time-mated to obtain experimental age-appropriate pups. IL-10-GFP mice pups were genotyped by PCR, and heterozygotes ( þ / À ) were used for studies. All animal protocols were prepared in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the LSUHSC/UTHSC Institutional Animal Care and Use Committee. Neonatal allergic asthma model. A neonatal mouse model of HDMinduced airway allergy was adapted from published methods. 10 Starting at 3 days of age, mice were exposed to DCB230 every day for 2 weeks (graphic in Figure1) . HDM extract (Greer Labs, Lenoir, NC) was administered to isofluorane-anesthetized mice intranasally starting on the last 3 days of the 2-week exposure, and then for 3 consecutive days per week for 3 consecutive weeks (10 mg per day during administration blocks 1 and 2; 15 mg per day during administration blocks 3 and 4). In DCB230-exposed groups, mice were only exposed on the same day and 2 h before HDM administration. All analyses/tissues were taken 24 h following the final protocol day.
Pulmonary mechanics. For invasive measurement of pulmonary function, mice were anesthetized and evaluated for AHR using flexiVent forced oscillation maneuvers (Scireq, Montreal, QC, Canada). Lung resistance to airflow was measured in response to increasing doses of (0, 12.5, 25, and 50 mg ml À 1 ) methacholine.
BAL cellularity and cytokines. BAL was collected in 1 ml phosphatebuffered saline containing 2% bovine serum albumin. Total cell counts were obtained, and cells were spun onto glass slides (one slide per animal sample) and stained with Hema-3 kit (Fisher Scientific, Hampton, NH). Cells were differentiated based on morphology/stain and a total of 200 cells per slide were counted. Cytokine levels were measured in cell-free BAL using a multiplex assay (Millipore, Billerica, MA). The following cytokines were assayed: granulocyte-macrophage colony-stimulating factor, interferon (IFN)-g, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, KC, tumor necrosis factor-a, vascular endothelial growth factor, and IP-10. Raw data were plotted against a standard curve using a five-parameter logistic regression to interpolate unknowns. Data presented exclude numbers beyond the sensitivity of the assay.
Circulating immunoglobulin. Serum was isolated from whole blood after 30 min of clotting followed by centrifugation. Samples were flash frozen in liquid nitrogen and stored at À 801C until further analysis. Levels of total IgE and IgG 1 were measured by enzyme-linked immunosorbent assay (ELISAs) according to the manufacturer's protocol (eBioscience, San Diego, CA). To assess HDM-specific IgE and IgG 1 levels in the serum, ELISA plates were coated with 50 mg ml À 1 HDM overnight at 41C, incubated with diluted serum (1:10 IgE; 1:10 000 IgG 1 ) and isotype-specific horse radish peroxidaselinked detection antibody (Southern Biotech, Birmingham, AL).
Lung histopathology. Lungs were excised, inflated at a constant fluid pressure of 25 cm with zinc-formalin, and fixed overnight. Fixed lungs were dehydrated, paraffin-embedded, and sectioned at 4 mm onto slides. Mucus-positive cells were quantified from sections stained with periodic acid-Schiff (PAS) and recorded as a percentage of PAS þ cells per total number of epithelial cells in randomly selected bronchi (ImageJ, Research Triangle Park, NJ) by an unbiased observer. All images were taken on a Zeiss microscope (Oberkochen, Germany) using AxioVision software (Oberkochen, Germany).
Quantitative real-time PCR. Total RNA was isolated from 40 mg lung tissue using RNAspin Mini Isolation Kit (GE, Pittsburgh, PA) and converted to cDNA using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). Quantitative real-time PCR was performed on a Roche LightCycler 480 using SYBR Green I Master (Roche, Indianapolis, IN) and gene-specific, intron-spanning primers for Muc5b (forward primer, 5 0 -CATGGATGGCTGCTTCTGT-3 0 ; reverse primer, 5 0 -TAAATTCGGCCACCGTGT-3 0 ), Muc5ac (forward primer, 5 0 -TCC CATTCTGGGTCCTAGC-3 0 ; reverse primer, 5 0 -GATTTCAGAG AGTCCTGTTGAGC-3 0 ), IL13 (forward primer, 5 0 -CCTCTGACCC TTAAGGAGCTTAT-3 0 ; reverse primer, 5 0 -CGTTGCACAGGGGA GTCT-3 0 ), IL10 (forward primer, 5 0 -CAGAGCCACATGCTCCTA GA-3 0 ; reverse primer, 5 0 -GTCCAGCTGGTCCTTTGTTT-3 0 ), and HPRT (forward primer, 5 0 -TCCTCCTCAGACCGCTTTT-3 0 ; reverse primer, 5 0 -CCTGGTTCATCATCGCTAATC-3 0 ). Single-amplicon quality was verified by melting curve analysis. Relative expression was calculated using DD Ct method normalized to reference gene HPRT.
Flow cytometry. Mice were killed and exsanguinated to prevent the flow of blood into the lungs and blood was removed by retrograde perfusion with phosphate-buffered saline. The lungs were excised, gently mechanically dissociated (Octodissociator; Miltenyi, Germany), and digested for 30 min at 37 1C in Hank's balanced salt solution supplemented with 1 mg ml À 1 collagenase I (Invitrogen, Grand Island, NY) and 150 ng ml À 1 DNase I (Sigma-Aldrich, St Louis, MO). After incubation, lung pieces were vigorously mechanically dissociated (Octodissociator) and mashed through a 40 mm cell strainer (BD Biosciences, San Jose, CA) followed by treatment with RBC lysis buffer (eBioscience) to get RBC-depleted, single-cell lung suspensions. For intracellular cytokine staining, cells were stimulated for 5 h at 37 1C in RPMI 1640 media (5% heat-inactivated fetal bovine serum) with 5 ng ml À 1 phorbol 12-myristate 13-acetate and 500 ng ml À 1 ionomycin (Sigma-Aldrich) in the presence of protein transport inhibitor brefeldin A (GolgiPlug; BD Biosciences). The following antibodies were used for T cells: eFluor450-CD3 (17A2), PerCP-CD4 (RM4-5), PE-IFN-g (XMG1.2), PE-Cy7-IL-4 (BVD6-24G2), FITC-IL-17 (eBio17B7), PE-CD25 (PC61.5), and FITC-Foxp3 (FJK-16s) and for DCs/Macs: FITC-CD11c (N418), PE-CD11b (M1/70), eFluor450-F4/ 80 (BM8), APC-Cy7-MHCII (M5/114.15.2), APC-IL-10 (JES5-16E3), and PerCP-Cy5.5-CD80 (16-10A1). A fixable live/dead marker was used to exclude dead cells (eFluor506/780). Cells were analyzed using flow cytometry (FACSCanto II; BD Biosciences), and all flow data were analyzed using the FlowJo software v.7.6.5 (Tree Star, Ashland, OR).
In vitro T-cell activation. C57BL/6 neonatal mice were exposed to DCB230 or control air starting at 3 days of age as described above for five consecutive days. After exposure on the fifth day, lungs were harvested, pooled according to exposure group, digested into singlecell suspensions, and DCs were positively selected using CD11c þ selection kit (StemCell, Vancouver, BC, Canada) followed by brief plating to select for non-adherence (to exclude macrophages). Concurrently, naive OVA 323-339 -specific CD4 þ T cells were positively selected using CD4 þ selection kit (StemCell) from single-cell spleen suspensions of age-matched OT-II neonates. DCs (5 Â 10 3 ) from Air/ DCB230-exposed neonate lungs were cultured with naive OVA 323-339specific CD4 þ T cells (5 Â 10 4 ) in the presence of 100 ng ml À 1 OVA 323-339 in 200 ml total of RPMI 1640 (10% heat-inactivated fetal bovine serum) for 72 h at 37 1C in a round-bottom 96-well plate. After 72 h, cytokine expression was measured from cell-free media supernatant using the method described above. Cells were washed with phosphate-buffered saline and either stained for Treg markers or stimulated to stain intracellularly for T-cell subsets. Stained cells were analyzed by flow cytometry.
Adoptive transfer. C57BL/6 neonatal mice were exposed to DCB230 or control air starting at 3 days of age as described above for five consecutive days. After exposure on the fifth day, lungs were harvested, pooled according to exposure group, digested into single-cell suspensions, and DCs were positively selected using CD11c þ selection kit (StemCell). After selection, DCs from both exposure groups were separately incubated at 37 1C for 2 h in RPMI 1640 with 10 mg ml À 1 OVA 323-339 . Following incubation, cells were washed with phosphatebuffered saline and adoptively transferred intranasally to age-matched OT-II neonates (1.5 Â 10 5 OVA 323-339 -loaded DCs per pup). After 7 days, pups were challenged intranasally with 2 mg OVA 323-339 to boost T-cell response, and then lungs were harvested 72 h later to analyze Treg levels using flow cytometry.
In vivo T effector response. OT-II neonates were exposed to DCB230 or control air starting at 3 days of age as described above for seven consecutive days. On exposure days 5 and 7, mice were challenged intranasally with 2 mg OVA 323-339 and lung T effector populations were assessed using flow cytometry 6 days after the final exposure/challenge. To measure responses in adult mice, a similar challenge/response time frame was used; mice were challenged intranasally with OVA 323-339 two times (48 h apart) and lung T effector populations were assessed using flow cytometry.
Statistical analysis. All data were analyzed using the GraphPad software (La Jolla, CA). Two-way analysis of variance (ANOVA) with Bonferroni post-tests or Student's t-test was used to determine differences between all groups. All results are expressed as mean ± s.e.m., representative of at least three independent experiments. Values of Pr0.05 were considered statistically significant. Statistical comparisons in Bonferroni post-tests were made within exposure groups (*P; Air vs. Air/HDM; DCB vs. DCB/HDM; Air vs. Air/OVA; DCB vs. DCB/OVA) or within allergen groups ( # P; Air vs. DCB; Air/HDM vs. DCB/HDM; Air/OVA vs. DCB/OVA).
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